Genentech announced that new data on its approved and investigational medicines for blood diseases will be presented at the 59th American Society of Hematology (ASH) Annual Meeting from December 9-12 in Atlanta. Ten Genentech medicines will be featured in over 75 abstracts, including 26 oral presentations, across eight blood diseases.
“At ASH this year, we look forward to presenting a wealth of data highlighting potential advances across the spectrum of blood diseases, from rare conditions like hemophilia A to common blood cancers like lymphoma,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development. “Our ongoing development program in hematology is one of the largest in this area, underscoring our commitment to developing practice-changing medicines and improving outcomes for people with diseases of the blood.”
Among Genentech’s clinical data to be featured at ASH are results from the ongoing trials for the investigational medicine emicizumab. Updated data with an additional six months of follow-up from the Phase III HAVEN 1 and HAVEN 2 studies evaluating the safety and efficacy of emicizumab in adults, adolescents and children with hemophilia A with inhibitors will be presented. The HAVEN 2 study will be highlighted as part of ASH’s official press program on December 9 at 7:30 A.M. ET. Additional results from the emicizumab clinical development program will be presented during the meeting, including preliminary data from the Phase III HAVEN 4 study exploring emicizumab prophylaxis administered every four weeks in people with hemophilia A with and without inhibitors, as well as real-world data from a non-interventional study in children under 12 years of age with hemophilia A with inhibitors.
Genentech will also be sharing data for medicines in late-stage development for a range of blood cancers. Highlights include results from a randomized Phase II study evaluating polatuzumab vedotin, an investigational anti-CD79b antibody drug conjugate, in combination with Rituxan® (rituximab) and bendamustine versus Rituxan and bendamustine for the treatment of people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Based on data from this study, polatuzumab vedotin was recently granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) and had previously received the PRIME (PRIority MEdicines) designation in Europe.
Additionally, results from studies of Gazyva® (obinutuzumab), including new data from the Phase III GALLIUM study in previously untreated follicular lymphoma, and data from the Phase III PrefMab study evaluating patient preference for Rituxan Hycela™ (rituximab and hyaluronidase human) as a treatment for DLBCL and follicular lymphoma will also be shared. Genentech and Biogen collaborate on Rituxan and Gazyva in the United States. Finally, results from multiple studies assessing the safety and efficacy of Venclexta™ (venetoclax) across chronic lymphocytic leukemia (CLL), multiple myeloma (MM) and acute myeloid leukemia (AML) will be presented. Venclexta is being developed by AbbVie and Genentech.
Filed Under: Drug Discovery
